🟢 Axsome Therapeutics is trading 4.75% up in pre-market with no clear catalyst identified

Axsome Therapeutics is trading at $176.35, up 4.75%, in pre-market; the reason for the move remains unclear.

• No clear company-specific announcement explaining the October 12 move was found; available coverage lists Q3 results on November 2, not a same-day catalyst.
• Recent analyst coverage includes Bank of America’s Buy rating, but reporting does not connect it to this pre-market move. Major indices are modestly higher, with none above the 0.5% threshold for a broad-market explanation.